|
|
|
|
Chest 2009,Jul,01;136(1):145-54; (PMID: 19255288)
[...]BACKGROUND: Long-acting beta(2)-agonists (LABAs) are recommended as add-on therapy to antiinflammatory treatment in patients with chronic persistent asthma. Results from individual studies evaluating the in vivo antiinflammatory effect of LABAs are conflicting.[...]
|
|
|
Thorax 2009,Jul,01;64(7):610-9; (PMID: 19406861)
[...]dietary intake of vitamins A, C and E may be associated with the occurrence of asthma. A systematic review and meta-analysis was conducted in accordance with MOOSE guidelines to determine whether [...]
|
|
|
J Allergy Clin Immunol 2009,Jun,01;123(6):1361-70.e7; (PMID: 19501237)
[...]However, published studies demonstrate differences concerning design and effect size, and conflicting results for asthma have been reported. OBJECTIVES: We sought to provide a more accurate estimate of FLG effect sizes and to better refine [...]
|
|
|
Allergy 2009,Jun,01;64(6):840-8; (PMID: 19392990)
[...]Meta-analyses failed to identify any consistent or clear benefits associated with use of omega 3 [atopic eczema: RR = 1.10 (95% CI 0.78-1.54); asthma: RR = 0.81 (95% CI 0.53-1.25); allergic rhinitis: RR = 0.80 (95% CI 0.34-1.89) or [...]
|
|
|
Ann Allergy Asthma Immunol 2009,Jun,01;102(6):487-94; (PMID: 19558007)
[...]The male predominance is even higher in allergic sensitization to D farinae than to D pteronyssinus. Further research is necessary regarding sex-specific differences in allergy and asthma.
|
|
|
COPD 2009,Jun,01;6(3):177-84; (PMID: 19811373)
BACKGROUND: Augmentation with exogenous alpha1-antitrypsin (alpha1-AT) is the only specific therapy for alpha1-AT deficiency. Uncertainty persists concerning its effectiveness. PURPOSE: To test the hypothesis that augmentation therapy in patients with alpha1-AT deficiency slows the decline in FEV1. STUDY SELECTION: Randomized and nonrandomized clinical studies with either parallel-group design or single cohort pre-post design were eligible if they compared augmentation therapy with a control regimen and if long-term (> 1 y) longitudinal FEV1 follow-up data were collected.[...]
|
|
|
Respir Med 2009,May,01;103(5):670-91; (PMID: 19155168)
BACKGROUND: The effectiveness of multiple interventions in asthma and chronic obstructive pulmonary disease (COPD) is unclear. OBJECTIVE: To examine the effectiveness of multiple interventions as compared to single interventions or usual care on health outcomes and health care utilisation within the context of integrated disease management in [...]
|
|
|
Clin Rehabil 2009,May,01;23(5):394-407; (PMID: 19389744)
[...]Botulinum toxin type A use was related to respiratory tract infection, bronchitis, pharyngytis, asthma, muscle weakness, urinary incontinence, falls, seizures, fever and unspecified pain.[...]
|
|
|
Allergy 2009,Apr,01;64(4):629-35; (PMID: 19133921) [FULL TEXT AVAILABLE]
[...]BACKGROUND: A genome-wide association study identified ORM1-like 3 (orosomucoid 1-like 3, ORMDL3) as an asthma candidate gene. Single nucleotide polymorphisms (SNPs) in the region including ORMDL3 on chromosome 17q21 were related to [...]
|
|
|
Curr Opin Allergy Clin Immunol 2009,Apr,01;9(2):168-76; (PMID: 19326509)
[...] (high daily dose, starting at least 4 months before pollen season) do show statistically significant improvement in symptom and medication scores for rhinitis and asthma in pollen allergy. New house dust mite studies still show inconsistent data. SUMMARY: Evidence of effect is confirmed for [...]
|
 1 2 3 4 5 6 7 8 
|
|
